Press Releases Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.43 ^USD	+2.93%		+3.18%	+6.98%

Apr. 15	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI
Apr. 15	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	Apr. 16	AQ
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	Apr. 15	AQ
Corporate Presentation: March 2024	Mar. 28	PU
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	Mar. 25	AQ
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	Mar. 22	AQ
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million	Mar. 18	AQ
Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split	Mar. 13	AQ
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split	Mar. 12	AQ
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update	Feb. 15	AQ
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update	Feb. 14	AQ
Outlook Therapeutics® Doses First Subject in NORSE EIGHT	Jan. 31	AQ
Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010	Jan. 24	AQ
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010	Jan. 23	AQ
OTLK FINAL DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK	Jan. 02	PR
Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline	Jan. 02	PR
OTLK DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action – OTLK	Jan. 01	BU
OUTLOOK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. and Encourages Investors to Contact the Firm	Dec. 29	BU
OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit	Dec. 28	PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK	Dec. 28	PR
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outlook Therapeutics, Inc. (OTLK)	Dec. 28	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Press Releases

Filters